Respiratory and allergy drugs: Practice MCQs

39 practice questions with answers and explanations across 6 drug classes. All practice questions · Respiratory and allergy drugs study guides · Download as flashcards (CSV)

Antihistamines

Revise the Antihistamines guide

  1. A three-month-old infant is brought to a rural clinic with vomiting, and a relative suggests a promethazine syrup left over from an older sibling. What is the correct response?

    1. Promethazine must not be used at this age because of potentially fatal respiratory depression
    2. Promethazine is acceptable if the amount is halved for body weight
    3. Promethazine is acceptable provided the infant is observed for one hour
    4. Promethazine is acceptable because syrups are safer than tablets
    Show answer

    Answer: A. Promethazine must not be used at this age because of potentially fatal respiratory depression

    The boxed warning states the product should not be used in pediatric patients less than 2 years of age because of the potential for fatal respiratory depression. No adjustment or observation makes it acceptable below that age.

  2. Which single property best explains why diphenhydramine causes sedation while fexofenadine does not?

    1. Penetration of the central nervous system
    2. Affinity for the H1 receptor
    3. Duration of receptor occupancy
    4. Selectivity for H2 over H1 receptors
    Show answer

    Answer: A. Penetration of the central nervous system

    Both are H1 antagonists. Rat distribution studies indicated fexofenadine does not cross the blood-brain barrier and no sedative or other central nervous system effects were observed, whereas diphenhydramine is labelled as having sedative effects.

  3. A patient taking fexofenadine for hay fever reports that it seems to have stopped working since they began a morning routine of indigestion remedy and a glass of orange juice. What is the most likely explanation?

    1. Reduced absorption caused by both the antacid and the fruit juice
    2. Rapid tolerance at the H1 receptor
    3. Induction of hepatic metabolism by orange juice
    4. Displacement of fexofenadine from plasma protein binding
    Show answer

    Answer: A. Reduced absorption caused by both the antacid and the fruit juice

    An aluminium- and magnesium-containing antacid taken within fifteen minutes decreased fexofenadine AUC by 41% and Cmax by 43%, and grapefruit, orange and apple juice may reduce its bioavailability and exposure.

  4. Which antihistamine is contraindicated in a patient with a prolonged QT interval?

    1. Hydroxyzine
    2. Loratadine
    3. Chlorphenamine
    4. Ketotifen eye drops
    Show answer

    Answer: A. Hydroxyzine

    The hydroxyzine label states that it is contraindicated in patients with a prolonged QT interval, following post-marketing reports of QT prolongation and torsade de pointes.

  5. An 82-year-old man with benign prostatic enlargement asks about an over-the-counter tablet for occasional sleeplessness that contains diphenhydramine. Which concern is most relevant?

    1. Antimuscarinic effects and sedation are both more troublesome at his age
    2. Diphenhydramine has no effect on the bladder
    3. The tablet contains no antihistamine because it is sold as a sleep aid
    4. Sedation is the only recognised problem in older people
    Show answer

    Answer: A. Antimuscarinic effects and sedation are both more troublesome at his age

    Antihistamines are more likely to cause dizziness, sedation and hypotension in elderly patients, and the label lists trouble urinating due to an enlarged prostate gland among the reasons to seek advice first.

  6. Which statement about second-generation antihistamines and the central nervous system is best supported by the product labels?

    1. Animal studies show little or no crossing of the blood-brain barrier, and one label calls the clinical significance unknown
    2. Human imaging has proved that no drug of the group enters the brain
    3. They enter the brain freely but lack activity at central H1 receptors
    4. They are converted in the brain to inactive metabolites
    Show answer

    Answer: A. Animal studies show little or no crossing of the blood-brain barrier, and one label calls the clinical significance unknown

    The desloratadine label reports rat and guinea-pig findings that it did not readily cross the blood brain barrier and adds that the clinical significance of this finding is unknown; fexofenadine's label reports the rat distribution result.

  7. A driver taking a sedating antihistamine says he feels perfectly alert. How should that self-assessment be weighed?

    1. It is unreliable, because measurable impairment can occur without obvious drowsiness
    2. It is reliable, because drowsiness always precedes impairment
    3. It is reliable if he has taken the drug before without incident
    4. It is unreliable only if he has also drunk alcohol
    Show answer

    Answer: A. It is unreliable, because measurable impairment can occur without obvious drowsiness

    Subjective symptoms such as yawning or drooping eyelids may not be apparent when effects on driving and psychomotor function are already present, and simulator steering after diphenhydramine was worse than at a blood alcohol content one-eighth of the legal limit.

Beta-2 agonist bronchodilators

Revise the Beta-2 agonist bronchodilators guide

  1. According to the current single-ingredient salmeterol label, what is the status of using a long-acting beta-2 agonist for asthma without a concomitant inhaled corticosteroid?

    1. Contraindicated
    2. Permitted at the lowest effective dose
    3. Permitted only in adults over 65
    4. Permitted for up to twelve weeks
    Show answer

    Answer: A. Contraindicated

    The boxed warning states that use of the product for the treatment of asthma as monotherapy without a concomitant inhaled corticosteroid is contraindicated, and that it should be used only as additional therapy in patients inadequately controlled on a steroid.

  2. A patient using an inhaled short-acting beta-2 agonist reports needing it far more often than previously. What does the labelling say this represents?

    1. A marker of deteriorating asthma requiring reassessment of the regimen
    2. Expected tolerance at the beta-2 receptor
    3. Evidence that the device is being used incorrectly
    4. A normal seasonal fluctuation requiring no action
    Show answer

    Answer: A. A marker of deteriorating asthma requiring reassessment of the regimen

    Increasing use of inhaled short-acting beta-2 agonists is described as a marker of deteriorating asthma, calling for immediate reevaluation with special consideration of additional inhaled or systemic corticosteroid.

  3. Which mechanism do the labels give for hypokalaemia caused by beta-2 agonists?

    1. Intracellular shunting of potassium
    2. Increased renal potassium excretion through aldosterone
    3. Reduced gastrointestinal potassium absorption
    4. Chelation of potassium in plasma
    Show answer

    Answer: A. Intracellular shunting of potassium

    The labels state that beta-adrenergic agonist medicines may produce significant hypokalaemia in some patients, possibly through intracellular shunting, and that the fall in serum potassium is usually transient.

  4. Immediately after taking an inhaled beta-2 agonist a patient becomes acutely more wheezy and breathless. What does the label direct?

    1. Treat at once with an inhaled short-acting bronchodilator, discontinue the agent and institute alternative therapy
    2. Repeat the same inhaler at double the number of actuations
    3. Continue the agent and add an oral antihistamine
    4. Withhold all bronchodilators and observe
    Show answer

    Answer: A. Treat at once with an inhaled short-acting bronchodilator, discontinue the agent and institute alternative therapy

    This is paradoxical bronchospasm, which may be life threatening. The label directs immediate treatment with an inhaled short-acting bronchodilator, immediate discontinuation of the causative product, and institution of alternative therapy.

  5. Why is a non-selective beta blocker a particular problem in a patient with asthma taking salbutamol?

    1. It blocks the pulmonary effect of the agonist and may itself produce severe bronchospasm
    2. It accelerates hepatic clearance of the agonist
    3. It prevents absorption of the agonist from the airway
    4. It converts the agonist into an inactive metabolite
    Show answer

    Answer: A. It blocks the pulmonary effect of the agonist and may itself produce severe bronchospasm

    The labels state that beta blockers not only block the pulmonary effect of beta agonists but may also produce severe bronchospasm in patients with asthma or chronic obstructive pulmonary disease.

  6. Which finding best illustrates that the inhaled route lowers the systemic burden of a beta-2 agonist?

    1. Tremor is reported in 20% of patients on oral salbutamol tablets but does not reach the 3% adverse reaction table for the inhalation aerosol
    2. The inhaled product has a longer duration of action than the oral product
    3. The inhaled product is contraindicated in cardiac disease while the oral product is not
    4. The oral product acts locally in the lung
    Show answer

    Answer: A. Tremor is reported in 20% of patients on oral salbutamol tablets but does not reach the 3% adverse reaction table for the inhalation aerosol

    The oral tablet label lists tremor and nervousness at 20% each, whereas the inhalation aerosol table of reactions occurring in at least 3% of patients contains throat irritation, viral respiratory infections, upper respiratory inflammation, cough and musculoskeletal pain.

  7. Which statement about the once-daily agents indacaterol and olodaterol is correct?

    1. Their single-ingredient products are licensed for chronic obstructive pulmonary disease and are not indicated for asthma
    2. They are licensed as rescue therapy for acute bronchospasm
    3. They are licensed for asthma as monotherapy in adults
    4. They act at beta-1 rather than beta-2 receptors
    Show answer

    Answer: A. Their single-ingredient products are licensed for chronic obstructive pulmonary disease and are not indicated for asthma

    The olodaterol label states it is not indicated to treat asthma, and the indacaterol summary of product characteristics states the product is only indicated for chronic obstructive pulmonary disease and should not be used in asthma because long-term outcome data are absent.

  8. Which combination is specifically flagged as potentiating the hypokalaemic effect of a beta-2 agonist?

    1. Xanthine derivatives, steroids or non-potassium-sparing diuretics
    2. Proton pump inhibitors and antacids
    3. Potassium-sparing diuretics and angiotensin receptor blockers
    4. Oral anticoagulants and statins
    Show answer

    Answer: A. Xanthine derivatives, steroids or non-potassium-sparing diuretics

    Concomitant treatment with xanthine derivatives, steroids or diuretics may potentiate any hypokalaemic effect of adrenergic agonists, and the European text names methylxanthine derivatives, steroids and non-potassium-sparing diuretics.

Inhaled and intranasal corticosteroids

Revise the Inhaled and intranasal corticosteroids guide

  1. A patient with asthma develops acute breathlessness and audible wheeze. Which statement about their inhaled corticosteroid is correct?

    1. It has no role in relieving the acute episode and a short-acting bronchodilator is required
    2. Doubling the number of puffs will produce bronchodilation within minutes
    3. It relaxes airway smooth muscle faster than a beta-2 agonist
    4. It is licensed specifically for the relief of acute bronchospasm
    Show answer

    Answer: A. It has no role in relieving the acute episode and a short-acting bronchodilator is required

    The fluticasone propionate inhalation aerosol is not indicated for the relief of acute bronchospasm, and its patient information directs that a short-acting bronchodilator is always used as the rescue medicine during a sudden asthma attack.

  2. Why do the labels for these inhalers direct that the mouth is rinsed with water without swallowing after each dose?

    1. To help reduce the risk of oropharyngeal candidiasis
    2. To prevent tooth enamel erosion from the propellant
    3. To improve absorption of the drug from the lung
    4. To avoid an unpleasant taste that reduces adherence
    Show answer

    Answer: A. To help reduce the risk of oropharyngeal candidiasis

    The beclometasone dipropionate inhalation aerosol label gives that exact reason for the instruction, and localised Candida albicans infection of the mouth and pharynx is a recognised consequence of steroid deposited on the oropharyngeal mucosa.

  3. A child on a long-term inhaled corticosteroid is reviewed in clinic. Which monitoring do the labels specifically direct?

    1. Routine measurement of growth, for example by stadiometry
    2. Annual bone marrow examination
    3. Three-monthly serum potassium
    4. Routine pulmonary function testing after each dose
    Show answer

    Answer: A. Routine measurement of growth, for example by stadiometry

    Orally inhaled corticosteroids may cause a reduction in growth velocity in paediatric patients, and the labels instruct that the growth of such patients is monitored routinely, with stadiometry named as the method.

  4. A patient taking fluticasone propionate is started on ritonavir. What is the principal concern?

    1. Raised systemic fluticasone exposure causing Cushing's syndrome and adrenal suppression
    2. Loss of asthma control from accelerated fluticasone clearance
    3. Precipitation of acute bronchospasm on first dose
    4. Irreversible reduction in inhaler device output
    Show answer

    Answer: A. Raised systemic fluticasone exposure causing Cushing's syndrome and adrenal suppression

    Ritonavir is a strong CYP3A4 inhibitor, and postmarketing reports describe clinically significant interactions with fluticasone propionate products resulting in systemic corticosteroid effects including Cushing's syndrome and adrenal suppression.

  5. Which adverse effect is characteristic of the intranasal rather than the orally inhaled route?

    1. Nasal septal perforation
    2. Dysphonia
    3. Oropharyngeal candidiasis
    4. Cough on inhalation
    Show answer

    Answer: A. Nasal septal perforation

    The fluticasone propionate nasal spray label groups epistaxis, nasal ulceration, Candida albicans infection, nasal septal perforation and impaired wound healing as local nasal effects, and postmarketing cases of septal perforation have been reported.

  6. In which population have regulators specifically advised vigilance for pneumonia during treatment with inhaled medicines containing a steroid?

    1. Patients with chronic obstructive pulmonary disease
    2. Children with seasonal allergic rhinitis
    3. Adults using a nasal spray for vasomotor rhinitis
    4. Patients after surgical removal of nasal polyps
    Show answer

    Answer: A. Patients with chronic obstructive pulmonary disease

    UK regulators advise physicians to remain vigilant for pneumonia and other lower respiratory tract infection in COPD patients treated with inhaled drugs that contain steroids, because the clinical features of such infections and of exacerbations frequently overlap.

  7. Which of these correctly describes beclometasone dipropionate?

    1. A prodrug rapidly hydrolysed to the active monoester 17-monopropionate
    2. An active drug cleared solely by renal excretion of unchanged parent
    3. A long-acting beta-2 agonist used for symptom relief
    4. A leukotriene receptor antagonist taken by mouth
    Show answer

    Answer: A. A prodrug rapidly hydrolysed to the active monoester 17-monopropionate

    Its label states that beclometasone dipropionate is a prodrug rapidly activated by hydrolysis to the active monoester, with lung slices metabolising the parent compound rapidly, and excretion is mainly faecal.

Antimuscarinic bronchodilators

Revise the Antimuscarinic bronchodilators guide

  1. By what mechanism does ipratropium widen the airway, according to its label?

    1. It antagonises acetylcholine and inhibits vagally mediated reflexes in the lung
    2. It stimulates beta-2 adrenoceptors on bronchial smooth muscle
    3. It inhibits phosphodiesterase and raises intracellular cyclic AMP
    4. It blocks cysteinyl leukotriene receptors in the airway wall
    Show answer

    Answer: A. It antagonises acetylcholine and inhibits vagally mediated reflexes in the lung

    The label describes ipratropium as an anticholinergic, or parasympatholytic, agent which appears from animal studies to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, and states that anticholinergics prevent the rise in intracellular cyclic GMP caused by acetylcholine acting on the muscarinic receptor.

  2. A patient receiving nebulised ipratropium by loosely fitting face mask develops eye pain, blurred vision and a red eye. What does the label identify as the risk?

    1. Precipitation or worsening of narrow-angle glaucoma from solution reaching the eye
    2. Corneal deposits caused by systemic accumulation of the drug
    3. Retinal toxicity proportional to cumulative inhaled exposure
    4. Optic neuritis as a hypersensitivity reaction
    Show answer

    Answer: A. Precipitation or worsening of narrow-angle glaucoma from solution reaching the eye

    The solution label advises that temporary blurring of vision, precipitation or worsening of narrow-angle glaucoma or eye pain may result if the solution comes into direct contact with the eyes, and recommends a nebuliser with mouthpiece rather than face mask to reduce that likelihood.

  3. Which pharmacokinetic figure best explains why tiotropium is a once-daily maintenance agent while ipratropium is not?

    1. A terminal half-life of approximately 25 hours in COPD, against about two hours for ipratropium
    2. Greater oral bioavailability of tiotropium after swallowing the inhaled fraction
    3. Higher protein binding of ipratropium in plasma
    4. Faster hepatic clearance of tiotropium by cytochrome P450 enzymes
    Show answer

    Answer: A. A terminal half-life of approximately 25 hours in COPD, against about two hours for ipratropium

    The tiotropium label gives a terminal half-life of around 25 hours in patients with COPD and bronchodilator effects lasting longer than 24 hours, while the ipratropium label gives an elimination half-life of about two hours after inhalation.

  4. Which history most directly warrants caution before an inhaled antimuscarinic is started?

    1. Bladder-neck obstruction due to prostatic hyperplasia
    2. Well-controlled hypothyroidism
    3. Previous deep vein thrombosis
    4. Mild iron-deficiency anaemia
    Show answer

    Answer: A. Bladder-neck obstruction due to prostatic hyperplasia

    The ipratropium aerosol label states that the drug is an anticholinergic and may cause urinary retention, and advises caution in patients with prostatic hyperplasia or bladder-neck obstruction; the umeclidinium and revefenacin labels carry the same warning.

  5. An inhaled antimuscarinic produces immediate wheeze and worsening breathlessness after a dose. What do the labels describe?

    1. Paradoxical bronchospasm, which may be life threatening
    2. An expected transient effect that settles with continued dosing
    3. Tachyphylaxis at the muscarinic receptor
    4. Rebound cholinergic tone from receptor upregulation
    Show answer

    Answer: A. Paradoxical bronchospasm, which may be life threatening

    The ipratropium aerosol label states that the product can produce paradoxical bronchospasm that can be life threatening, and directs that treatment be stopped and other treatments considered; the umeclidinium label directs immediate discontinuation and treatment with an inhaled short-acting bronchodilator.

  6. Which statement about tiotropium and asthma is correct?

    1. The soft-mist inhaler is indicated for once-daily maintenance treatment of asthma from six years of age
    2. It is indicated as a reliever inhaler for acute asthma symptoms
    3. It has no asthma indication in any formulation
    4. It replaces inhaled corticosteroid maintenance therapy in asthma
    Show answer

    Answer: A. The soft-mist inhaler is indicated for once-daily maintenance treatment of asthma from six years of age

    The Respimat label carries a long-term, once-daily maintenance indication in asthma for patients six years of age and older, states that the product is not indicated for the relief of acute bronchospasm, and notes that maximum benefit in lung function may take up to four to eight weeks.

  7. Why does an inhaled antimuscarinic cause fewer systemic anticholinergic effects than an oral one?

    1. It is a quaternary ammonium compound that is poorly absorbed, so the effect is local and site-specific
    2. It is rapidly destroyed by esterases in plasma before reaching any receptor
    3. It binds irreversibly to airway receptors and cannot dissociate into the circulation
    4. It is actively pumped back into the airway lumen by efflux transporters
    Show answer

    Answer: A. It is a quaternary ammonium compound that is poorly absorbed, so the effect is local and site-specific

    The ipratropium label describes a quaternary amine that is not readily absorbed into the systemic circulation from the lung surface or the gastrointestinal tract, and states that the bronchodilation after inhalation is primarily a local, site-specific effect rather than a systemic one.

Leukotriene receptor antagonists

Revise the Leukotriene receptor antagonists guide

  1. Which statement best describes how zileuton differs mechanistically from montelukast?

    1. Zileuton inhibits 5-lipoxygenase and so reduces formation of the leukotrienes, whereas montelukast blocks the CysLT1 receptor
    2. Zileuton blocks the CysLT1 receptor more selectively than montelukast does
    3. Zileuton is a bronchodilator acting at beta-2 adrenoceptors
    4. Zileuton inhibits cyclo-oxygenase and reduces prostaglandin formation
    Show answer

    Answer: A. Zileuton inhibits 5-lipoxygenase and so reduces formation of the leukotrienes, whereas montelukast blocks the CysLT1 receptor

    The zileuton label describes it as an inhibitor of 5-lipoxygenase that thus inhibits LTB4, LTC4, LTD4 and LTE4 formation, while montelukast binds with high affinity and selectivity to the CysLT1 receptor rather than to prostanoid, cholinergic or beta-adrenergic receptors.

  2. A prescriber is considering montelukast purely for seasonal allergic rhinitis in a patient whose symptoms are mild and who has not tried anything else. What does the labelling require?

    1. Use is reserved for patients with an inadequate response or intolerance to alternative therapies
    2. Montelukast is the preferred first choice for all allergic rhinitis
    3. Montelukast may be used first provided liver enzymes are checked monthly
    4. Allergic rhinitis is not an indication for montelukast at any point
    Show answer

    Answer: A. Use is reserved for patients with an inadequate response or intolerance to alternative therapies

    The boxed warning states that the benefits may not outweigh the risks in some patients, particularly where symptoms are mild and adequately treated with alternatives, and reserves allergic rhinitis use for inadequate response or intolerance to alternative therapies. Liver enzyme monitoring belongs to zileuton, not montelukast.

  3. Which monitoring requirement belongs specifically to zileuton?

    1. Serum ALT before treatment, monthly for the first three months, then every two to three months for the rest of the first year
    2. Prothrombin time measured before every dose
    3. Annual eosinophil count in all patients
    4. Serum potassium at each review
    Show answer

    Answer: A. Serum ALT before treatment, monthly for the first three months, then every two to three months for the rest of the first year

    That schedule is set out in the zileuton label, which also contraindicates the drug in active liver disease or persistent enzyme elevations at or above three times the upper limit of normal. Prothrombin time is monitored only where warfarin is co-prescribed.

  4. Which of these interactions is documented for zafirlukast?

    1. A clinically significant increase in prothrombin time when given with warfarin
    2. Loss of oral contraceptive efficacy through enzyme induction
    3. A doubling of digoxin clearance
    4. Precipitation of serotonin syndrome with selective serotonin reuptake inhibitors
    Show answer

    Answer: A. A clinically significant increase in prothrombin time when given with warfarin

    The zafirlukast label records a clinically significant increase in prothrombin time on coadministration with warfarin and requires close monitoring with anticoagulant dose adjustment. The other three options are not described in that label.

Methylxanthines

Revise the Methylxanthines guide

  1. A patient stable on oral theophylline is admitted and stops smoking. One week later he is nauseated, tremulous and tachycardic. What is the most likely explanation?

    1. Loss of smoking-induced enzyme activity has reduced theophylline clearance
    2. Nicotine withdrawal alone accounts for all of the findings
    3. Reduced gastrointestinal absorption has lowered the concentration
    4. Theophylline has begun to induce its own metabolism
    Show answer

    Answer: A. Loss of smoking-induced enzyme activity has reduced theophylline clearance

    The label reports that abstinence from tobacco smoking for one week causes a reduction of approximately 40% in theophylline clearance, and directs careful attention to dose reduction and frequent monitoring of concentrations in patients who stop smoking.

  2. Which statement best reflects what the theophylline label says about the drug's mechanism of action?

    1. The mechanisms are not known with certainty, with animal studies suggesting phosphodiesterase III and IV inhibition
    2. Bronchodilation is proven to result from adenosine A1 receptor antagonism
    3. The drug acts as a direct beta-2 adrenoceptor agonist on airway smooth muscle
    4. It works entirely through inhibition of leukotriene synthesis
    Show answer

    Answer: A. The mechanisms are not known with certainty, with animal studies suggesting phosphodiesterase III and IV inhibition

    The label states that while the mechanisms of action are not known with certainty, studies in animals suggest that bronchodilation is mediated by inhibition of two isozymes of phosphodiesterase, PDE III and to a lesser extent PDE IV.

  3. Which co-prescribed antibiotic carries a specific labelled warning about serious and fatal reactions when given with theophylline?

    1. Ciprofloxacin
    2. Amoxicillin
    3. Azithromycin
    4. Co-trimoxazole
    Show answer

    Answer: A. Ciprofloxacin

    The ciprofloxacin label states in capitals that serious and fatal reactions have been reported with concurrent administration, including cardiac arrest, seizure, status epilepticus and respiratory failure, because ciprofloxacin inhibits cytochrome P-450 1A2.

  4. In which pair of conditions does the theophylline label describe clearance as decreased by 50% or more?

    1. Congestive heart failure and hepatic insufficiency
    2. Hyperthyroidism and cystic fibrosis
    3. Renal impairment in adults and hypertension
    4. Iron deficiency anaemia and obesity
    Show answer

    Answer: A. Congestive heart failure and hepatic insufficiency

    The label states that clearance is decreased by 50% or more both in patients with congestive heart failure and in patients with hepatic insufficiency such as cirrhosis, acute hepatitis or cholestasis. Hyperthyroidism and cystic fibrosis are listed among the factors that increase clearance.

  5. Which methylxanthine is licensed for the short-term treatment of apnoea of prematurity?

    1. Caffeine citrate
    2. Aminophylline
    3. Pentoxifylline
    4. Theophylline extended-release tablets
    Show answer

    Answer: A. Caffeine citrate

    Caffeine citrate injection and oral solution are indicated for the short term treatment of apnoea of prematurity in infants between 28 and under 33 weeks gestational age.

  6. Which electrolyte abnormality was recorded in the large majority of acute theophylline overdose cases in the series tabulated in the label?

    1. Hypokalaemia
    2. Hypernatraemia
    3. Hypocalcaemia
    4. Hyperkalaemia
    Show answer

    Answer: A. Hypokalaemia

    Low potassium appears in 85% and 79% of acute overdose cases across the two series in the label's table of manifestations of theophylline toxicity, and in 44% and 43% of chronic overdosage cases.